Clinical Trials on Invasive Carcinoma

Total 24070 results

Xoft, Inc.
Icad, Inc.

Active, not recruiting

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Ductal Carcinoma in Situ | Invasive Ductal Carcinoma

United States, Portugal, Australia
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy (CAREFOR)

Stage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Lobular Breast Carcinoma | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma

United States
Mayo Clinic

Recruiting

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Invasive Breast Carcinoma | Breast Adenocarcinoma | Resectable Breast Carcinoma

United States
RPCR, Inc.
CyberKnife Coalition

Recruiting

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

Ductal Carcinoma in Situ | Invasive Ductal Carcinoma of Female Breast

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
Centre Hospitalier Universitaire Dijon

Completed

Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the "Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in Invasive Candidiasis. (EMPIRICAND)

Invasive Candidiasis; Treatment With Echinocandin

France
Xoft, Inc.
Icad, Inc.

Withdrawn

An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"

Ductal Carcinoma In Situ | Invasive Ductal Carcinoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Invasive Breast Carcinoma | HER2/Neu Negative | Bilateral Breast Carcinoma

United States
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Hoffmann-La Roche; Brigham and Women's...

Terminated

Capecitabine in Women With Operable Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage III Breast Cancer | Primary Invasive Breast Cancer

United States
RenJi Hospital
Peking University First Hospital; Xiangya Hospital of Central South University and other collaborators

Recruiting

Circulating Tumour DNA and Urine Tumor DNA Detection of Minimal Residual Disease in Locally Advanced Upper Tract Urothelial Carcinoma With Radical Nephroureterectomy: A Cohort Study

Muscle Invasive Upper Tract Urothelial Carcinoma

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Ductal Breast Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Invasive Ductal Breast Carcinoma

United States
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
University of Bologna

Unknown

A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis

Invasive Candidiases | Abdominal Infection

Italy
Soonchunhyang University Hospital
Ministry of Health & Welfare, Korea

Active, not recruiting

The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness (MUST-BE)

Ductal Carcinoma in Situ | Invasive Cancer

Korea, Republic of
Roswell Park Cancer Institute

Completed

Exercise in Improving Health and Quality of Life in Breast Cancer Survivors

Invasive Breast Carcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer

Invasive Ductal Carcinoma, Breast
Astellas Pharma Global Development, Inc.
Seagen Inc.

Recruiting

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Carcinoma in Situ | Urinary Bladder Neoplasms | Non-muscle Invasive Bladder Cancer | Carcinoma Transitional Cell | NMIBC

United States, Canada, France, Spain, United Kingdom, Germany
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial Carcinoma | Stage 0 Bladder Urothelial Carcinoma

United States
University of Utah

Recruiting

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

Invasive Lobular Breast Carcinoma

United States
University Hospital, Lille

Recruiting

Early Discontinuation of Empirical Antifungal Therapy and Biomarkers (SEAT)

Invasive Candidiasis

France
University Hospital, Limoges

Completed

Pharmacokinetics of Micafungin in Patients of Intensive Care Units (MI-K)

Invasive Candidiasis

France
University Medical Center Groningen

Completed

Variability of Fluconazole Concentration in Critically Ill Patients

Invasive Candidiasis

Netherlands
Merck Sharp & Dohme LLC

Completed

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Invasive Candidiasis
Merck Sharp & Dohme LLC
Mycoses Study Group

Terminated

Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Invasive Candidiasis
University Hospital, Grenoble

Completed

Empirical Antifungal Treatment in ICUS (EMPIRICUS)

Invasive Candidiasis

France
Mycoses Study Group
Merck Sharp & Dohme LLC

Completed

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU) (MSG-01)

Invasive Candidiasis

United States
Marwa Mahmoud Hassan
Qena Oncology Center

Enrolling by invitation

Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma

Invasive Breast Cancer

Egypt
Toronto Sunnybrook Regional Cancer Centre
Canadian Breast Cancer Foundation

Completed

The Prone Breast Radiation Therapy Trial

Invasive Breast Cancer | Ductal Carcinoma In Situ

Canada
University Medical Center Groningen

Completed

Optimal Dosage of Caspofungin in Critically Ill Patients

Critically Ill | Suspected Invasive Candidiasis

Netherlands
Cancer Institute and Hospital, Chinese Academy...
Hoffmann-La Roche

Unknown

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Carcinoma, Invasive Ductal, Breast

China
Yung Shin Pharm. Ind. Co., Ltd.

Completed

Evaluate Bioequivalence of Micafungin (50mg/Vial)

Invasive Candidiasis

Taiwan
Duke University
Children's Hospital of Philadelphia

Completed

BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia (BIOPIC)

Invasive Candidiasis

United States, Saudi Arabia, Greece, Spain
Merck Sharp & Dohme LLC

Terminated

Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Candidiasis, Invasive
Hasan Al-Dorzi
King Fahad Medical City

Completed

Invasive Candidiasis in Saudi ICUs (ICIP-SA)

Invasive Candidiasis

Saudi Arabia
Pfizer
Vicuron Pharmaceuticals

Completed

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

Candidiasis

United States
Medical University of Graz
Medical University Innsbruck

Completed

NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis (NOBICS)

Invasive Candidiasis

Austria
Fadoi Foundation, Italy

Terminated

Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin (EPICA1)

Invasive Candidiasis

Italy
Kevin Watt

Completed

Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation

Invasive Candidiasis

United States
Duke University
Pfizer

Completed

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Invasive Candidiasis

United States
Henan Cancer Hospital

Recruiting

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Intraoperative Complications | Perfusion; Complications | High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
Varian, a Siemens Healthineers Company
Rigshospitalet, Denmark; Herlev Hospital

Recruiting

Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach (ARTIA-Vesica)

Muscle-Invasive Bladder Carcinoma

Denmark
Elypta
Lund University

Recruiting

AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study (AUR93A)

Muscle-Invasive Bladder Carcinoma

Sweden, Denmark, Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital...

Not yet recruiting

Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.

Muscle-Invasive Bladder Carcinoma
IRCCS San Raffaele
Bristol-Myers Squibb

Recruiting

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NURE-Combo)

Muscle-Invasive Bladder Carcinoma

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Invasive Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive

United States
C2i Genomics
Fox Chase Cancer Center; Baylor College of Medicine; New York University; The Cleveland... and other collaborators

Terminated

Clinical Performance Evaluation of the C2i-Test

Muscle-Invasive Bladder Carcinoma

United States

Clinical Trials on Invasive Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations